An observational study in Tendinopathy, sponsored by Universitaire Ziekenhuizen KU Leuven. Completed at 1 site in Belgium. Per ClinicalTrials.gov, last updated 2021-03-11.
Sponsored by Universitaire Ziekenhuizen KU Leuven · Observational
To evaluate the outcome of percutaneous paratenon release for chronic midportion Achilles tendinopathy.
Since 2011 the percutaneous procedure took the place of the open release of the paratenon for the surgical treatment for chronic midportion Achilles tendinopathy in the investigators' center. In this study the investigators re-evaluate the patients undergoing percutaneous surgery since then in order to compare the outcome with the excellent results cited in literature. The patients will be contacted and asked to participate completing a VAS-score, a VISA-A score and agreeing with a clinical examination.
Approving by the Ethical Committee of UZLeuven is pending.
413 studies on the registry are indexed under Tendinopathy; 64 are open to participants now.
This study's enrollment of 8 is below the median of 67 across 52 observational studies indexed under Tendinopathy.
Browse Tendinopathy studies →Universitaire Ziekenhuizen KU Leuven is the lead sponsor of 928 studies on the registry; 261 are open to participants now.
Of its 5 completed or terminated interventional studies of FDA-regulated products, 0 (0%) have results posted.
Counted across the registry records on this site, refreshed daily.
patients that underwent percutaneous paratenon release for chronic midportion Achilles tendinopathy
Exclusion Criteria:
patients that underwent percutaneous release of the paratenon for chronic midportion Achilles tendinopathy
Procedure: percutaneous paratenon release
percutaneous paratenon release for chronic midportion Achilles tendinopathy
VISA-A-score
specific questionnaire about (mal-)function of Achilles tendon
Time frame: 3 months
SF-36-score
questionnaire about well-being
Time frame: 3 months
VAS-score
questionnaire about pain
Time frame: 3 months
This study is completed, as verified in Mar 2021. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Universitaire Ziekenhuizen KU Leuven